Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ASPH | Q12797 | 2/20 | 0.43 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31092297 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAKDM4EASPHKDM8 | |
| Nitrous Acid SCHEMBL29105413 | 0.94 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAKDM4EASPHKDM8 | |
| SCHEMBL31092300 | 0.86 | KMT2A (0.49) | SMN1; SMN2LMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL801078 | 0.86 | KMT2A (0.49) | SMN1; SMN2LMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL16563790 | 0.82 | ATR (0.49) | SMN1; SMN2LMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL31693360 | 0.80 | ASPH (0.55) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL27888702 | 0.80 | KDM4E (0.43) | SMN1; SMN2KDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL15758083 | 0.80 | ASPH (0.55) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL29105412 | 0.80 | RAB9A (0.40) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL29105406 | 0.79 | NUDT1 (0.46) | SMN1; SMN2LMNAKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115557886-B | Synthesis method of 3-nitroisonicotinic acid methyl ester | 山西永津集团有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-115650909-B | Synthesis method of 3-amino isonicotinic nitrile | 山西永津集团有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-115650909-A | Synthetic method of 3-amino isonicotinic nitrile | 山西永津集团有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115557886-A | Synthetic method of 3-nitroisonicotinic acid methyl ester | 山西永津集团有限公司 | 2023-01-03 | — | — | CN | claimed |
| EP-4725942-A1 | COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE | Sibylla Biotech S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025264818-A1 | STAT6 MODULATORS AND METHODS OF USES THEREOF | RAYTHERA, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4651907-A1 | DRUG CONJUGATES AND METHODS OF PREPARING AND USING THE SAME | Adcentrx Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4567035-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-06-11 | — | — | EP | disclosed |
| CN-119654324-A | Novel compounds as hypoxia inducible factor 1 (HIF-1) inhibitors or Vascular Endothelial Growth Factor (VEGF) inhibitors and pharmaceutical compositions comprising the same | 株式会社次代生物科学 | 2025-03-18 | — | — | CN | disclosed |
| CN-115557886-B | Synthesis method of 3-nitroisonicotinic acid methyl ester | 山西永津集团有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-115557886-B | Synthesis method of 3-nitroisonicotinic acid methyl ester | 山西永津集团有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-115650909-B | Synthesis method of 3-amino isonicotinic nitrile | 山西永津集团有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| EP-2366691-B1 | THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO LTD (CN) | 2015-04-15 | — | — | EP | disclosed |
| US-8940770-B2 | Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof | BEIJING YILING BIOENGINEERING CO., LTD. (CN) | 2015-01-27 | — | — | US | disclosed |
| US-8940770-B2 | Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof | BEIJING YILING BIOENGINEERING CO., LTD. (CN) | 2015-01-27 | — | — | US | disclosed |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2014-03-13 | — | — | US | disclosed |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2014-03-13 | — | — | US | disclosed |
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2012-03-22 | — | — | US | disclosed |
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | BEIJING YILING BIOENGINEERING CO., LTD (CN) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071515-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | ENPP1, DPYD, NME2 | SMN1; SMN2 3153/4885LMNA 2967/4885KDM4E 1856/4885 |
| US-20140073796-A1 | NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF | ENPP1, DPYD, NME2 | SMN1; SMN2 3153/4885LMNA 2967/4885KDM4E 1856/4885 |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | SMN1; SMN2 1776/4885LMNA 2375/4885KDM4E 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.